Cited by 22Smoking Behavior and CessationAttention Deficit Hyperactivity DisorderSubstance Abuse Treatment and Outcomes

Treating Nicotine Dependence by Targeting Attention-Deficit/ Hyperactivity Disorder (ADHD) With OROS Methylphenidate: The Role of Baseline ADHD Severity and Treatment Response

Open access
Nunes, Edward V., Covey, Lirio S., Brigham, Gregory, Hu, Mei-Chen, Levin, Frances R., Somoza, Eugene C., Winhusen, Theresa M.·2013·The Journal of Clinical Psychiatry

Abstract

OBJECTIVE: To determine whether treatment of attention-deficit/hyperactivity disorder (ADHD) with osmotic-release oral system (OROS) methylphenidate promotes abstinence from smoking among smokers with ADHD who have greater severity of ADHD symptoms at baseline or greater improvement in ADHD during treatment. METHOD: This is a secondary analysis of data from a randomized, double-blind, 11-week trial conducted between December 2005 and January 2008 at 6 clinical sites; the original trial was sponsored by the National Drug Abuse Clinical Trials Network. Adult cigarette smokers (aged 18-55 years) who met DSM-IV criteria for ADHD were randomly assigned to OROS methylphenidate (72 mg/d) (n = 127) or matching placebo (n = 128). All participants received nicotine patches (21 mg/d) and weekly individual smoking cessation counseling. Logistic regression was used to model prolonged abstinence from smoking (ascertained by self-report and breath carbon monoxide testing) as a function of treatment, baseline ADHD Rating Scale-IV (ADHD-RS) score, change in ADHD-RS score during treatment, and their interactions. RESULTS: Treatment interacted with both ADHD-RS score at baseline (P = .01) and change in ADHD-RS score during treatment (P = .008). Among patients with higher ADHD-RS scores (> 36) at baseline and the most improvement in ADHD during treatment (ADHD-RS change score ≥ 24), 70.0% of those who took OROS methylphenidate achieved abstinence from smoking compared to 36.8% of those who took placebo (P = .02). In contrast, among patients with the lowest ADHD-RS baseline scores (≤ 30), 30.3% of those who took OROS methylphenidate achieved abstinence from smoking compared to 60.7% of those who took placebo (P = .02). CONCLUSIONS: OROS methylphenidate, in combination with nicotine patch, may be an effective treatment for nicotine dependence among smokers with more severe ADHD and more robust response of ADHD symptoms to medication. OROS methylphenidate may be counterproductive among smokers with lower severity of ADHD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00253747.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.12m08155

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Osmotic controlled-release methylphenidate for 11 weeks in adult smokers with severe ADHD promoted abstinence in part by improving ADHD symptoms.

    “In addition, another study found that osmotic controlled-release delivery of methylphenidate for 11 weeks to adult smokers with severe ADHD promoted abstinence to smoking in these individuals in part by improving ADHD symptoms (Nunes et al., 2013).”

    From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Nunes et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [1]Compton WM Thomas YF Stinson FS Grant BF Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007 64 5 566 76 17485608
  2. [31]Sobell LC Sobell MB Allen J Lit-ten R Timeline follow back: A technique for assessing self-reported ethanol consumption Techniques to Assess Alcohol Consumption 1992 Humana Press, Inc New Jersey

Cited by

Sorted by citations

Authors
Nunes, E. V., Covey, L. S., Brigham, G., Hu, M.-C., Levin, F. R., Somoza, E. C., & Winhusen, T. M.
Affiliations
  • New York State Psychiatric Institute (US)
  • University of Cincinnati (US)
  • Columbia University (US)
  • Cincinnati VA Medical Center (US)
Corresponding author
Nunes, Edward V.
Venue
The Journal of Clinical Psychiatry
Published
2013-10-15
Volume
74
Issue
10
Pages
983-990
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2015543066
Cited by
22
References
47
Citations by year
2026: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 3 · 2012: 1
FWCI
1.16
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (U10DA013035, K24DA022412, U10DA013732, K23DA021512, K24DA029647)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
nicotine dependence, attention deficit hyperactivity disorder, OROS methylphenidate, smoking cessation, ADHD symptom severity, nicotine patch, treatment interaction
MeSH terms
Administration, Oral, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Biological Availability, Double-Blind Method, Female, Humans, Male, Methylphenidate, Middle Aged, Psychiatric Status Rating Scales, Tobacco Use Disorder, Logistic Models, Smoking Cessation, Treatment Outcome, Drug Monitoring, Diagnostic and Statistical Manual of Mental Disorders, Tobacco Use Cessation Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review